The STAR Market of the Shanghai Stock Exchange, a Nasdaq-style bourse for pre-revenue startup companies, has rejected one biotech’s application for an initial public offering for the first time since STAR's inception in 2019.
Shanghai-based Shanghai HaiHe Pharmaceutical Co., Ltd was officially turned away after a listing committee meeting called by the Shanghai...